Aurinia Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, disclosing net income of $37.4 million for the second quarter and $71.8 million for the first half of 2026.

Key Highlights

  • Q2 net product sales: $79,412 thousand, up from $66,574 thousand in Q2 2025.
  • Six-month net product sales: $152,975 thousand, compared to $126,545 thousand for the same period in 2025.
  • Q2 net income: $37,414 thousand, or $0.28 diluted earnings per share, versus $21,513 thousand, or $0.16 diluted, in Q2 2025.
  • Total assets: $792,262 thousand as of June 30, 2026, up from $751,587 thousand at December 31, 2025.
  • Cash, cash equivalents and restricted cash: $179,832 thousand at June 30, 2026, compared to $80,213 thousand at December 31, 2025.
  • Share repurchases: The company repurchased 4,974 thousand common shares in the first half of 2026 under its Share Repurchase Plan for a combined $74,931 thousand.
  • Shares outstanding: 132,907 thousand as of June 30, 2026, with 133,051,168 shares outstanding as of August 5, 2026.

Aurinia's Revenue Growth and Financial Position in the First Half of 2026

According to the filing, Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) reported total revenue of $83,220 thousand for the three months ended June 30, 2026, compared to $70,008 thousand for the same period in 2025. For the six months ended June 30, 2026, total revenue reached $160,925 thousand versus $132,473 thousand in the prior-year period. Total revenue comprised net product sales and license, collaboration and royalty revenue, the latter of which amounted to $3,808 thousand for Q2 2026 and $7,950 thousand for the first half of 2026, the company disclosed.

The filing reported income from operations of $46,341 thousand for Q2 2026 and $87,763 thousand for the six-month period. Operating expenses for Q2 2026 totaled $36,879 thousand, which included cost of revenue of $6,555 thousand, selling, general and administrative expenses of $23,508 thousand, research and development expenses of $13,050 thousand, and other income, net, of $6,234 thousand. Income tax expense for the second quarter was $11,372 thousand, compared to $643 thousand in Q2 2025, according to the filing.

On the balance sheet, total shareholders' equity rose to $614,864 thousand at June 30, 2026, from $581,331 thousand at December 31, 2025. The accumulated deficit narrowed to $577,599 thousand from $649,368 thousand over the same span. Short-term investments stood at $263,291 thousand as of June 30, 2026. The company reported finance right-of-use lease assets of $65,152 thousand and related finance lease liabilities totaling $60,422 thousand (current and non-current combined), the filing noted. Deferred revenue, including current and non-current portions, was $18,073 thousand at June 30, 2026.

What Was Disclosed

Aurinia Pharmaceuticals disclosed its unaudited condensed consolidated financial statements for the three and six months ended June 30, 2026, covering revenue growth, profitability, balance sheet position, share repurchase activity, and changes in shareholders' equity.